Segment Reporting (Tables)

6 Months Ended

Jun. 30, 2025

Segment Reporting [Abstract]

Schedule of Segment Profit or Loss, Including Significant Segment Expenses

Segment loss, including significant segment expenses, for the three and six month periods ended June 30, 2025 and 2024 is as follows (in thousands):


									Three Months Ended June 30,												Six Months Ended June 30,
									2025						2024						2025						2024
Product revenues, net									$	107,415					$	90,340					$	200,238					$	165,840
Less:
			Cost of product revenues (excluding amortization of intangible assets)						28,075						20,964						49,353						38,421
			ARIKAYCE external R&D expenses						11,003						14,896						23,124						28,822
			Brensocatib external R&D expenses						33,560						37,806						54,221						57,324
			TPIP external R&D expenses						20,649						14,773						29,802						28,555
			Other external R&D expenses						28,445						14,917						56,528						28,192
			R&D compensation and benefit-related expenses						56,389						43,908						109,947						85,368
			SG&A compensation and benefit-related expenses						51,320						35,087						106,156						67,672
			Other segment items(a)						127,650						90,379						247,345						167,168
			Depreciation						2,484						1,436						4,367						3,024
			Amortization of intangible assets						1,263						1,263						2,526						2,526
			Change in fair value of deferred and contingent consideration liabilities						59,000						103,700						77,300						91,800
			Investment income						(13,225)						(10,285)						(27,131)						(19,068)
			Interest expense						21,245						21,267						42,814						42,309
			Provision for income taxes						1,243						838						2,155						1,427
Segment net loss									$	(321,686)					$	(300,609)					$	(578,269)					$	(457,700)

(a) Other segment items include stock-based compensation, professional fees, and facility-related expenses.